+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 28 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects vision. This study aims to learn if a medicine called tiespectus also known as MK-8748 or EYE201 can treat NVAMD as well as the standard treatment called aflibercept. The trial is a pivotal Phase 23 study that compares these treatments in people newly diagnosed with NVAMD. Participants are randomly assigned to one of three groups one group receives a low dose of tiespectus, another receives a high dose of tiespectus, and the third group receives aflibercept. Those in the tiespectus groups get three initial injections every 4 weeks, then continue injections every 8 weeks until week 48, followed by treatments at intervals based on their individual response up to week 92. The aflibercept group receives three initial injections followed by injections every 8 weeks until week 92. During the study, participants are regularly assessed for changes in their best-corrected visual acuity using ETDRS letters from baseline to one year. Other evaluations include eye imaging to measure retinal thickness and monitoring for any adverse events up to approximately 96 weeks. The study lasts over one year with ongoing visits to track treatment response and safety.

Age: 50Years +All GendersPhase 2Phase 3
71 locations
E

Actively Recruiting

Researchers are evaluating a new treatment called MK-8748 for people with diabetic macular edema DME, a condition that can cause vision loss in people with diabetes. This trial compares MK-8748 to an existing standard treatment called aflibercept to see if MK-8748 works as well. The study is a randomized, double-masked, pivotal phase 3 trial focusing on treatment safety and effectiveness. Participants are assigned to one of three groups a low dose of MK-8748, a high dose of MK-8748, or the standard aflibercept treatment. Those receiving MK-8748 will get five initial injections every 4 weeks, then continue every 8 weeks until week 48, followed by personalized treatment intervals up to week 100. Participants in the aflibercept group receive injections every 4 weeks for five doses, then every 8 weeks up to week 100. During the study, participants will have regular eye exams and vision tests to measure changes in visual acuity and eye thickness. Researchers will monitor how well treatments reduce retinal swelling and improve diabetic retinopathy severity using imaging and questionnaires. Safety will be closely observed, including adverse events and antibody levels, over approximately two years. The main focus is to assess the change in best-corrected visual acuity from baseline to one year.

Age: 18Years +All GendersPhase 3
20 locations
P

Actively Recruiting

Researchers are investigating the effects of APL-3007 combined with SyfovrePegcetacoplan APL-2 in patients with geographic atrophy caused by age-related macular degeneration AMD. This Phase 2 randomized, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacodynamics of these treatments in this eye condition. The study involves multiple centers and uses a masked design to ensure unbiased results. Participants will be assigned to one of three groups two receiving different doses or frequencies of APL-3007 in combination with pegcetacoplan APL-2, and one receiving a placebo along with pegcetacoplan APL-2. The study will evaluate the treatments given as multidose regimens. The treatments focus on complement C3 inhibition to potentially impact disease progression. Throughout the study, participants will undergo assessments including artificial intelligence-based imaging to measure retinal pigment epithelium lesion area and photoreceptor degeneration, safety evaluations through adverse event reporting and visual acuity tests, and blood tests to assess serum markers. These evaluations occur over 12 months to monitor changes from baseline. Participants involvement includes regular visits for these assessments, with the study tracking treatment effects and safety over the duration.

Age: 60Years +All GendersPhase 2
78 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of different doses of a new medicine called NNC0519-0130 in people living with chronic kidney disease, some of whom have type 2 diabetes and are overweight or obese. This Phase 2 study also compares NNC0519-0130 to semaglutide, an already prescribed medicine, and a placebo to see how they may improve kidney function. Participants will be randomly assigned to receive once-weekly subcutaneous injections of NNC0519-0130 with a fixed dose escalation until reaching a maintenance dose, semaglutide with a similar dosing schedule, or a placebo matching NNC0519-0130. The treatment period lasts up to 43 weeks with several dosing schemes and groups. During the study, participants will have their kidney function monitored through urine albumin-to-creatinine ratio changes at weeks 12, 24, and 36. Other assessments include estimated glomerular filtration rate, body weight changes, waist circumference, blood pressure, and glycated hemoglobin levels. Safety will be evaluated by tracking adverse events throughout the trial duration. Participants will be regularly assessed to understand the medicines effects and safety.

Age: 18Years +All GendersPhase 2
147 locations
S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations
C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
R

Actively Recruiting

Researchers are studying the safety and effectiveness of tabirafusp tedromer compared to aflibercept in people with diabetic macular edema DME, a condition causing vision impairment related to diabetes. This phase 3 randomized trial aims to evaluate these two treatments administered by injection into the eye, focusing on improving vision clarity. Participants receive intravitreal injections of either tabirafusp tedromer or aflibercept. Tabirafusp tedromer is given once every 4 weeks for six doses, then either every 8 weeks or individualized between every 4 to 24 weeks depending on the group. Aflibercept is administered every 4 weeks for five doses, followed by every 8 weeks. The study compares these dosing schedules over time to assess treatment impact. During the trial, participants undergo regular eye exams to measure best corrected visual acuity at week 52 and other safety assessments. The study includes monitoring of treatment effects and side effects through scheduled visits with injections and vision tests. Participation lasts through the treatment and evaluation period, allowing researchers to gather data on vision changes and overall safety.

Age: 18Years +All GendersPhase 3
52 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.

Age: 18Years +All GendersPhase 2
147 locations
E

Actively Recruiting

Researchers are evaluating the medicine BI 1815368 in adults aged 18 and older who have a specific eye condition called centre-involved diabetic macular edema CI-DME, a type of diabetic macular edema. The purpose is to determine if BI 1815368 helps improve vision and to identify the best dose. This randomized, double-masked, placebo-controlled Phase 2 trial is sponsored by Boehringer Ingelheim. The study has two parts. In the first part, participants are randomly assigned to take either BI 1815368 tablets or placebo tablets that look identical but contain no medicine. In the second part, participants are randomly assigned to one of four groups three groups receive different daily doses of BI 1815368, and one group receives placebo. All participants take tablets twice daily for about 11 months. Participants stay in the study for about one year, visiting the study site at least 16 times. Those taking metformin have three extra visits. At each visit, doctors check vision, record any health issues, and take detailed pictures of the eye using advanced imaging. Researchers compare vision changes over time between groups to assess the medicines effect. Safety and tolerability are also monitored throughout the study.

Age: 18Years +All GendersPhase 2
97 locations
C

Actively Recruiting

Researchers are evaluating the investigational medicine BI 764524 for adults with moderate to severe non-proliferative diabetic retinopathy, an eye condition related to diabetes. The study aims to determine whether BI 764524 helps improve this condition and to identify the best treatment plan. This phase 2 trial randomly assigns participants to five groups to compare different dosing regimens and controls, including a group receiving aflibercept, an approved diabetic retinopathy treatment available only in the USA. Participants receive varying numbers of injections of BI 764524 in one eye over one year, with some visits involving sham injections that mimic the procedure without a needle to maintain blinding. One group receives only sham injections, and another group in the USA receives aflibercept or sham injections. The treatment period lasts 52 weeks, after which researchers evaluate improvements in eye severity and complications. Throughout the 1.5-year study, participants visit the study site at least 16 times for regular eye exams, vision tests, and imaging scans to monitor the eye condition and treatment effects. Researchers assess improvements using the Diabetic Retinopathy Severity Scale and watch for vision-threatening complications. Safety is monitored by tracking any adverse effects. The study helps understand how BI 764524 affects diabetic retinopathy over time.

Age: 18Years +All GendersPhase 2
90 locations

1-10 of 28

1